Analysis of Chlamydia pneumoniae-infected monocytes following incubation with a novel peptide, acALY18, implicates the inflammasome in clearance of infection by Balin, Brian J. et al.
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
Scholarly Posters
2011
Analysis of Chlamydia pneumoniae-infected
monocytes following incubation with a novel
peptide, acALY18, implicates the inflammasome in
clearance of infection
Brian J. Balin
Philadelphia College of Osteopathic Medicine, brianba@pcom.edu
James D. Thacker
TherimuneX Pharmaceuticals, Inc,
Charles Lim
Philadelphia College of Osteopathic Medicine, thecharlielim@gmail.com
Corey M. Caruthers
Philadelphia College of Osteopathic Medicine
Susan T. Hingley
Philadelphia College of Osteopathic Medicine, susanh@pcom.edu
See next page for additional authorsFollow this and additional works at: http://digitalcommons.pcom.edu/posters
Part of the Bacterial Infections and Mycoses Commons, Nervous System Diseases Commons,
and the Neurology Commons
This Book is brought to you for free and open access by DigitalCommons@PCOM. It has been accepted for inclusion in Scholarly Posters by an
authorized administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Balin, Brian J.; Thacker, James D.; Lim, Charles; Caruthers, Corey M.; Hingley, Susan T.; Zoga, Juliana; and Appelt, Denah M.,
"Analysis of Chlamydia pneumoniae-infected monocytes following incubation with a novel peptide, acALY18, implicates the
inflammasome in clearance of infection" (2011). Scholarly Posters. Book 7.
http://digitalcommons.pcom.edu/posters/7
Authors
Brian J. Balin, James D. Thacker, Charles Lim, Corey M. Caruthers, Susan T. Hingley, Juliana Zoga, and Denah
M. Appelt
This book is available at DigitalCommons@PCOM: http://digitalcommons.pcom.edu/posters/7
Analysis of Chlamydia pneumoniae-infected monocytes following incubation with a
novel peptide, acALY18, implicates the inflammasome in clearance of infection 
Chlamydia pneumoniae infection may be a trigger for the pathology observed in sporadic late-
onset Alzheimer’s disease as a function of initiating neuroinflammation following entry of the
organism into the brain. We have hypothesized that one entry mechanism may be by blood-
borne infected monocytes trafficking the infection into the brain. This study focuses on
infection of monocytes in vitro followed by analysis using immunofluorescence labeling and
RT-PCR-microarray techniques. The microarrays utilized consisted of an Alzheimer’s disease
pathway array and an innate and adaptive immunity array from SAbiosciences. Analysis by
real time PCR for both gene arrays was performed on uninfected and C. pneumoniae-infect-
ed THP1 monocytes at 48 hr post-infection. In addition, we analyzed innate and adaptive
immunity gene regulation changes following treatment of infected cells with a unique pep-
tide, acALY18, derived from the endogenously expressed endoplasmic reticulum protein
TRPC1. The peptide appears to stimulate the innate immune system through activation of
the inflammasome. C. pneumoniae prominently infected THP1 monocytes at 24-48hr.
Numerous large inclusions were identified using specific chlamydial monoclonal antibodies.
Monocyte gene expression changes induced by infection with C. pneumoniae revealed signif-
icant up-regulation of 45 genes in the Alzheimer’s disease pathway. These included genes
involved in: b-amyloid processing and clearance, apoptosis, proteases and protein kinases,
and lipid metabolism. In contrast, infection resulted in significant changes in 30 genes gov-
erning innate and adaptive immunity including those for: the inflammatory response, host
defense against bacteria, cytokines, chemokines, and an antibacterial humoral response.
Intriguingly, following incubation of C. pneumoniae-infected cells with the acALY18 peptide
(25-50nM) at 24hr post-infection, there was significant clearance of the organism from the
monocytes as well as up-regulation of 38 genes. Our data suggest that C. pneumoniae
infection of monocytes has a profound effect on gene regulation for both innate and adap-
tive immunity and for Alzheimer’s disease. Stimulating the innate immune response using the
novel peptide, acALY18, promotes clearance of C. pneumoniae from infected monocytes;
thereby implicating the inflammasome as a key component in eradicating this infection.
Infection with the respiratory obligate intracellular bacterium Chlamydia pneumoniae has
been shown to be involved in numerous human respiratory and non-respiratory diseases
including: community-acquired pneumonia and bronchitis (1), atherosclerosis and heart
disease (2; 3), and late-onset Alzheimer’s disease (4;5). C. pneumoniae gains access to the
circulation upon infection of monocytes, and potentially of lymphocytes (6;7). Chronic
persistence of C pneumoniae in circulating monocytes is likely, and may facilitate systemic
infection (8) through transfer of C. pneumoniae between infected monocytes and peripher-
al endothelial cells (9). Our laboratory has evidence that the monocyte is one key cell type
that may carry C. pneumoniae into the CNS (10; 11), and may implicate C. pneumoniae as
a major risk factor in the development of late-onset Alzheimer’s disease (for review see 12).
Impacting this infection with a therapeutic regimen may diminish the potential for infec-
tion in the CNS as well as elsewhere in the body. Antibiotics may be used in combating this
type of infection; however, an antibiotic regimen would not necessarily be prudent given
issues of antibiotic penetration to different anatomical sites, efficacy against chronic/persis-
tent organisms and driving organisms into a persistent state, antibiotic resistance, and the
potential for the development of super-infections. Therefore, we are studying an alternative
method of combating infection by inducing the innate immune system to better respond
and eradicate this type of infection. Specifically, we are using a recently discovered lipopep-
tide (acALY-18) derived from the endogenous endoplasmic reticulum TRPC1 protein that
has been found to activate the innate immune response in fibroblasts and keratinocytes
(13). Our preliminary data suggest that this lipopeptide activates C. pneumoniae-infected
monocytes resulting in heightened clearance of the organism when compared to untreated
infected cells.  Therefore the lipopeptide (acALY-18) may be a viable candidate for treating
C. pneumoniae infections in Alzheimer’s disease.
acALY-18 has been determined to have identical sequence homology to the internal
sequence of amino acids at positions 558-574 in the transient receptor potential channel-
related protein 1 (TRPC1) (13).  No significant homology with other known proteins or
peptides has been noted. The TRPC family of proteins belongs to the TRP superfamily of
non-voltage-gated cation channel proteins of which at least seven TRPC family members
have been described in mammals (14).  Members of the TRPC family, including TRPC1,
appear to be conserved within the animal kingdom and the trp gene family also appears to
be expressed in a wide variety of tissues and cell types including immune cells (for review
see 15). The topology of TRPC1 has been deduced (16) and the amino acid sequence com-
prising the acALY-18 peptide appears to reside in the extracellular region between the sixth
and seventh membrane spanning units. Sequence homology of this region of TRPC1 with
the other members of the TRPC family is relatively low (~30%) as compared to ~80% for
the N-terminal sequence (14).  
The function of acALY-18 appears to involve the intracellular induction of specific
cytokines/chemokines and this may be independent of activation through toll-like recep-
tors. The induction appears to activate the innate immune response by activating the
inflammasome (17). Inflammasomes are cytosolic multiprotein complexes containing cyto-
plasmic receptors of the NALP (NACHT, LRR and pyrin domain-containing protein)
family as central components (17). These inflammasomes can be activated by bacterial tox-
ins, and by endogenous danger signals from intracellular pathogens (18; 19). Furthermore,
lysosomal damage has been shown to induce NALP3 activation (20). 
Using a peptide such as acALY-18, which was originally derived and identified from the
naturally occurring TRPC1 protein (13), to induce the innate immune response, provides
an unique opportunity to improve processing and clearance of intracellular pathogens, such
as C. pneumoniae. Harnessing this more natural approach in combating infection may have
implications for Alzheimer’s disease therapy that incorporates a variety of environmental
factors, including infection, as major risks and/or causative agents in disease pathogenesis.
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Introduction
Abstract Results
 C. pneumoniae infection of human monocytes alters gene expression for mark-
ers of the innate and adaptive immune response
 Altered gene expression prevents adequate clearance of the organism
from the professional killing cells thereby promoting persistent infec-
tion. 
 Ineffective clearance of infection maintains chronic turn-on of an
inflammatory response by infected monocytes as reflected by specific
gene expression
 C. pneumoniae infection of human monocytes alters gene expression for mark-
ers of Alzheimer’s disease     
 Increased expression of specific genes demonstrates the effect of intra-
cellular infection on genes associated with all aspects of 
cellular function
 These data support our contention that C. pneumoniae infection is a
“trigger” for altered gene expression in the pathogenesis of Alzheimer’s
disease  
 The novel PDAG peptide acALY-18 induces expression of genes 
associated with innate and adaptive immunity to effectively reduce 
C. pneumoniae infection of monocytes
 acALY-18 may be a viable candidate for treating this infection in
Alzheimer’s disease. 
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Figure 1: The PDAG peptide (acALY-18) sequence is homologous with an extracellular
loop of TRPC1, a transmembrane Ca 2+ channel protein. Percent homology between
TRPC1 and other members of the TRP family is indicated.  A putative pore loop is indi-
cated between transmembrane segments S5 and S6. The region indicated by the red circle
is the pDAG peptide sequence. Arrowheads indicate small gaps present in homology of
TRPC1 relative to other TRP family members. 
Figure 2: Percent cells infected with Chlamydia pneumoniae (A) as determined by counting
infected cells (green labeling) in THP1 monolayers untreated (B) or treated (C) with
acALY-18 peptide at 24hrs post-infection and processed at 48hrs post-infection.
Figure 3: Fold regulation of expression in a subset of genes in Chlamydia pneumoniae AR-39
infected cells (MOI =1) relative to PDAG peptide (acALY-18) treated cells at 48hr post-
infection. Data for infected cells were derived from 4 sets of experiments. Data for acALY-18
treated infected cells were derived from 2 experiments. Genes were detected using an innate
and adaptive immunity RT2PCR array from SABiosciences (Qiagen) *p < .05, **p > .05 and < 0.1
relative to uninfected THP1 monocyte gene expression.
Figure 4: Fold regulation of expression in a subset of genes in Chlamydia pneumoniae
AR-39 infected cells (MOI =1) relative to uninfected cells. Data were derived from 4
sets of experiments. Genes were detected using an Alzheimer's disease RT2PCR array
from SABiosciences (Qiagen) *p < .05, **p > .05 and < 0.1.
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Function Gene symbol Gene name
β-amyloid processing & clearance
Secretases ADAM9 ADAM metallopeptidase domain 9
APH1A Anterior pharynx defective 1 homolog A (C. elegans)
BACE2 β-site APP-cleaving enzyme 2
CTSB Cathepsin B
PSEN1 Presenilin 1
Other peptidases IDE Insulin-degrading enzyme
PLAU Plasminogen activator, urokinase
β-amyloid clearance through APLP1 β-amyloid precursor-like protein 1
endocytosis APP β-amyloid precursor protein
LRP6 LDL receptor-related protein 6
Other genes involved in  A2M α-2-macroglobulin
β-amyloidmetabolism APBB1 β-amyloid precursor protein-binding, family B, member 1
UBQLN1 Ubiquilin 1
Synaptic formation
ACHE Acetylcholinesterase (YT blood group)
APBA1 Amyloid beta (A4) precursor protein-binding, family A, 
member1
CHAT Choline acetyltransferase
Lipid, lipoprotein & cholesterol 
metabolism
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1
APOA1 Apolipoprotein A-I
APOE Apolipoprotein E
CLU Clusterin
LRP1 LDL-related protein 1 (α-2-macroglobulin receptor)
LRP8 LDL receptor-related protein 8 (apolipoprotein e receptor)
Apoptosis
CASP3 Caspase 3, apoptosis-related cysteine peptidase
CASP4 Caspase 4, apoptosis-related cysteine peptidase
EP300 E1A binding protein p300
Proteases 
CTSC Cathepsin C
CTSD Cathepsin D
CTSL Cathepsin L1
Function Gene symbol Gene name
Inflammatory response
IL1A Interleukin 1, alpha
IL1B Interleukin 1, beta
IL1F10 Interleukin 1 family, member 10 (theta)
IL1F5 Interleukin 1 family, member 5 (delta)
IL1F8 Interleukin 1 family, member 8 (eta)
IL1R1 Interleukin 1 receptor, type I
IL1RN Interleukin 1 receptor antagonist
IRAK2 Interleukin-1 receptor-associated kinase 2
MYD88 Myeloid differentiation primary response gene (88)
TLR1 Toll-like receptor 1
TLR10 Toll-like receptor 10
TLR6 Toll-like receptor 6
TLR8 Toll-like receptor 8
TNF Tumor necrosis factor (TNF superfamily, member 2)
Host defense against bacteria
CAMP Cathelicidin antimicrobial peptide
DEFB4 Defensin, beta 4
DMBT1 Deleted in malignant brain tumors 1
IRF1 Interferon regulatory factor 1
NCF4 Neutrophil cytosolic factor 4, 40kDa
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha
S100A12 S100 calcium binding protein A12
Cytokines, chemokines & their receptors
CCL2 Chemokine (C-C motif ) ligand 2
CXCR4 Chemokine (C-X-C motif ) receptor 4
IFNA1 Interferon, alpha 1
IFNB1 Interferon, beta 1, fibroblast
IFNGR1 Interferon gamma receptor 1
IL1F7 Interleukin 1 family, member 7 (zeta)
IL1F9 Interleukin 1 family, member 9
IL6 Interleukin 6 (interferon, beta 2)
Antibacterial humoral response
COLEC12 Collectin sub-family member 12
CYBB Cytochrome b-245, beta polypeptide
LY96 Lymphocyte antigen 96
Septic shock
Apoptosis  associated with ADORA2A Adenosine A2a receptor
septic shock IL10 Interleukin 10
PROC Protein C (inactivator of coagulation factors Va and VIIIa)
Other genes involved in HMOX1 Heme oxygenase (decycling) 1
septic shock SERPINA1 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antit
rypsin), member 1
SERPINE1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1
TREM1 Triggering receptor expressed on myeloid cells 1
Function Gene symbol Gene name
Protein kinases
CDC2 Cell division cycle 2, G1 to S & G2 to M
CDK5 Cyclin-dependent kinase 5
GSK3A Glycogen synthase kinase 3 alpha
GSK3B Glycogen synthase kinase 3 beta
PRKCB Protein kinase C, beta
PRKCE Protein kinase C, epsilon
PRKCI Protein kinase C, iota
Cell signaling molecules
G-protein coupled receptor APLP2 β-amyloid precursor-like protein 2
GNB1 G protein, β 1
GNB4 G protein, β 4
GNG10 G protein, γ 10
GNG11 G protein, γ 11
GNG3 G protein, γ 3
GNG4 G protein, γ 4
GNGT2 G protein, γ transducing activity polypeptide 2
Other signaling molecules APBA3 Amyloid beta (A4) precursor protein-
binding, family A, member3
GNB2 G protein, β 2
IL1A Interleukin 1, α
Oxidoreductases & oxidative stress
HSD17B10 Hydroxysteroid (17-β) dehydrogenase 10
UQCRC1 Ubiquinol-cytochrome c reductase core protein I
UQCRC2 Ubiquinol-cytochrome c reductase core protein II
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